• At 2 years, superiority not confirmed for amphilimus-eluting stent in diabetes

    6 days ago - By Healio

    BOSTON - After 2 years, PCI with amphilimus-eluting stents was noninferior to PCI with zotarolimus-eluting stents in patients with diabetes, not confirming the potential superiority signal observed at 1 year.
    The 2-year results of the second-generation drug-eluting stents in diabetes randomized trial were presented at TCT 2022.
    The 1-year findings, presented at TCT 2021 and published in the European Heart Journal, indicated that the amphilimus-eluting stents may be superior to zotarolimus-eluting stents in patients with diabetes at
    Read more ...